Identification of distinct disease activity trajectories in patients with psoriatic arthritis receiving tofacitinib: a post hoc analysis of two phase 3 studies

Identification of distinct disease activity trajectories in patients with psoriatic arthritis receiving tofacitinib: a post hoc analysis of two phase 3 studies

Objective To capture variations in tofacitinib treatment response in psoriatic arthritis (PsA) by identifying patient groups with distinct disease activity trajectories.Methods Data were pooled post hoc from two phase 3 studies (OPAL Broaden, OPAL Beyond) in patients with PsA receiving tofacitinib 5...

Full description

Saved in:

Bibliographic Details
Main Authors:	Laura C Coates, Dafna Gladman, Mikhail Volkov, David Gruben, William Tillett, Stefanie Hahne
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2025-06-01
Series:	RMD Open
Online Access:	https://rmdopen.bmj.com/content/11/2/e005250.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysis
by: Dafna D. Gladman, et al.
Published: (2024-12-01)

Results of studying the clinical efficacy and safety of tofacitinib in the treatment of psoriatic arthritis
by: T. V. Korotaeva, et al.
Published: (2019-05-01)

Effect of tofacitinib treatment on active MRI sacroiliitis in psoriatic arthritis patients
by: E. E. Gubar, et al.
Published: (2021-05-01)

EFFICACY AND SAFETY OF TOFACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS IN REAL CLINICAL PRACTICE
by: E. Yu. Loginova, et al.
Published: (2020-06-01)

Validity and score interpretation of the 12-item Psoriatic Arthritis Impact of Disease: an analysis of pooled data from two phase 3 trials of bimekizumab in patients with psoriatic arthritis
by: Laure Gossec, et al.
Published: (2024-02-01)

Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond
by: Philip J Mease, et al.
Published: (2019-06-01)

Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs
by: Philip J Mease, et al.
Published: (2019-05-01)

Comparative efficacy of tofacitinib and adalimumab in patients with psoriatic arthritis in real clinical practice. Data from the Russian nationwide register of patients with psoriatic arthritis
by: E. Yu. Loginova, et al.
Published: (2021-06-01)

Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studies
by: Peter C. Taylor, et al.
Published: (2022-07-01)

Search for predictors of achieving minimal disease activity during tofacitinib therapy in patients with psoriatic arthritis
by: L. D. Vorobyova, et al.
Published: (2023-12-01)

Impact of tofacitinib on patient-reported outcomes in patients with psoriatic arthritis. Data from the real clinical practice
by: L. D. Vorobyeva, et al.
Published: (2022-07-01)

Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study
by: Philip J Mease, et al.
Published: (2019-06-01)

IS PSORIATIC ARTHRITIS REALLY PSORIATIC?
by: Sh. F. Erdes
Published: (2014-12-01)

A Case Series Report on the Effect of Tofacitinib on Joint Inflammation and Gut Microbiota Composition in Psoriatic Arthritis Patients Naive to Biologic Agents
by: Andrea Picchianti Diamanti, et al.
Published: (2024-11-01)

Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study
by: Laure Gossec, et al.
Published: (2024-02-01)

Identification of miR‐190a‐5p and miR‐26b‐5p as Potential microRNA Biomarkers for Psoriatic Arthritis
by: Omar F. Cruz‐Correa, et al.
Published: (2025-07-01)

NEW APPROACHES TO PHARMACOTHERAPY OF RHEUMATOID ARTHRITIS: TOFACITINIB
by: E. L. Nasonov
Published: (2014-06-01)

Experience with tofacitinib in the treatment of resistant rheumatoid arthritis
by: A. R. Babaeva, et al.
Published: (2015-06-01)

THE PLACE OF TOFACITINIB IN THE TREATMENT STRATEGY OF RHEUMATOID ARTHRITIS
by: V. I. Mazurov, et al.
Published: (2018-05-01)

Letter to the Editor Regarding the Article "Impact of Race on the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of Pooled Clinical Trials"
by: YanRan Qiu, et al.
Published: (2025-03-01)

Psoriasis and Psoriatic Arthritis in ChildhoodPsoriasis and Psoriatic Arthritis in Childhood
by: Nikolay N. Murashkin, et al.
Published: (2020-12-01)

A Response to: Letter to the Editor Regarding Impact of Race on the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of Pooled Clinical Trials
by: Grace C. Wright, et al.
Published: (2025-03-01)

Uveitis in patients with axial spondyloarthritis or psoriatic arthritis: a post hoc analysis from placebo-controlled phase III studies with secukinumab
by: Jan Brandt-Jürgens, et al.
Published: (2025-06-01)

Early psoriatic arthritis
by: E. Y. Loginova, et al.
Published: (2008-12-01)

Nail disease in psoriatic arthritis. Data from the Russian Psoriatic Arthritis Registry
by: E. E. Gubar, et al.
Published: (2021-10-01)

Early detection to improve outcome in people with undiagnosed psoriatic arthritis: the PROMPT research programme including RCT
by: Neil McHugh, et al.
Published: (2025-06-01)

Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a post hoc analysis of a phase III trial
by: Philip J Mease, et al.
Published: (2019-06-01)

A case of vitiligo regression in a patient with psoriasis and psoriatic arthritis receiving adalimumab therapy
by: N. S. Rudneva, et al.
Published: (2021-12-01)

Tofacitinib is a modern solution to the problem of resistant rheumatoid arthritis
by: I. V. Menshikova, et al.
Published: (2019-05-01)

Tofacitinib Citrate for Ulcerative Keratitis in a Patient with Rheumatoid Arthritis
by: Philip B. Meadow, et al.
Published: (2014-01-01)

Tofacitinib treatment for psoriatic skin lesions associated with Aicardi-Goutières syndrome 7/Singleton-Merten syndrome 1
by: Shanice Beerepoot, et al.
Published: (2025-04-01)

Methotrexate in the treatment of rheumatoid arthritis and psoriatic arthritis
by: N. V. Chichasova, et al.
Published: (2021-06-01)

Distinguishing rheumatoid arthritis from psoriatic arthritis
by: Joseph F Merola, et al.
Published: (2018-08-01)

Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics
by: Fabrizio Cantini, et al.
Published: (2017-01-01)

Standards of therapy of psoriatic arthritis
by: T V Korotaeva, et al.
Published: (2009-06-01)

Ixekizumab in the treatment of psoriatic arthritis
by: Yu. L. Korsakova, et al.
Published: (2024-12-01)

Therapy for psoriatic arthritis with infliximab
by: V V Badokin, et al.
Published: (2009-03-01)

Management of patients with psoriatic arthritis
by: Yulia Leonidovna Korsakova
Published: (2012-03-01)

Modern pharmacotherapy of psoriatic arthritis
by: Yu. L. Korsakova, et al.
Published: (2019-03-01)

Axial involvement in psoriatic arthritis
by: E. E. Gubar, et al.
Published: (2022-12-01)